# China NMPA Drug Inspection - Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. - Astragalus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/aba57897-f842-4c0e-b53b-f28b7fd3afd5/
Source feed: China

> China NMPA drug inspection for Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd. published July 06, 2017. Drug: Astragalus. On July 6, 2017, the State Food and Drug Administration (SFDA) issued Announcement No. 101, detailing non-compliance acr

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 101 of 2017 from the State Administration of Traditional Chinese Medicine regarding 12 batches of substandard prepared slices of traditional Chinese medicine.
- Company Name: Anhui Zhongmeitang Traditional Chinese Medicine Pieces Co., Ltd.
- Publication Date: 2017-07-06
- Drug Name: Astragalus
- Inspection Finding: Properties
- Action Taken: Control measures such as sealing and seizing have been taken, requiring enterprises to suspend sales and use, recall products, and rectify the situation; cases have been filed to investigate illegal acts of producing and selling substandard drugs, and the results of the investigation have been made public.
- Summary: On July 6, 2017, the State Food and Drug Administration (SFDA) issued Announcement No. 101, detailing non-compliance across 12 batches of traditional Chinese medicine decoction pieces from 10 companies, following testing by the China National Institutes for Food and Drug Control (NIFDC). Key violations included impurities found in nine batches of Centipeda minima from manufacturers such as Jilin Yuanli Pharmaceutical Co., Ltd., Anhui Baihetang Traditional Chinese Medicine Decoction Pieces Co., Ltd., Shaoyang Shennong Traditional Chinese Medicine Technology Development Co., Ltd., and Chongqing Kangdi Pharmaceutical Co., Ltd. Additionally, Anhui Bozhou Zhewan Traditional Chinese Medicine Pieces Co., Ltd. had one batch of Pangdahai containing aflatoxin, while Guangxi Zhangyitang Traditional Chinese Medicine Pieces Co., Ltd. had two batches of Huangqi that failed appearance standards. Under the framework of Articles 73, 74, and 75 of the 'Drug Administration Law of the People's Republic of China,' provincial food and drug administrations were mandated to implement immediate control measures. These actions included sealing and seizing non-compliant products, ordering sales suspension, product recalls, and requiring rectifications. Furthermore, authorities were instructed to investigate the illegal production and sale, publicly disclose handling results within three months, and report on the overall situation. Companies were also provided a mechanism to dispute product authenticity, with severe penalties threatened for confirmed manufacturers of substandard drugs.

Company: https://www.globalkeysolutions.net/companies/anhui-zhongmeitang-traditional-chinese-medicine-pieces-co-ltd/4a1dc5e0-b023-4d15-8511-24385790ddb3/